OBJECTIVE	To determine the antiviral activity , pharmacokinetics , pharmacodynamics , safety , and tolerability of several dose levels of oral TBR-652 monotherapy in HIV-1-infected , antiretroviral experienced , CCR5 antagonist-naive subjects .\